Law Offices of Gary Martin Hays & Associates
P.C.
75 Ponce De Leon Ave NE Ste 101
Atlanta,
GA 30308(470) 294-1674
www.garymartinhays.com
By Colleen Murphy | September 16, 2024
"Plaintiffs assert that lenzilumab's prospects of success were overstated, that defendants failed to disclose material adverse nonpublic information concerning the scientific merits of repurposing lenzilumab as a COVID treatment as part of a scheme to mislead investors into purchasing shares of Humanigen stock," U.S. District Judge William J. Martini said.
By ALM Staff | August 26, 2024
This suit was surfaced by Law.com Radar.
By Michelle Morgante | August 22, 2024
California-based Amgen has filed a patent infringement suit to stop Samsung Bioepis from developing bone-treatment drugs that would rival two of its top-performing products.
By Colleen Murphy | August 15, 2024
"Through its most recent hirings, STAAR aims to essentially hire the entire J&J Vision marketing team at a critical time for J&J Vision's business and in the midst of its execution of its short-term and long-term strategic plans," the complaint said.
By Sulaiman Abdur-Rahman | August 6, 2024
"Mrs. [Henrietta] Lacks's cells were obtained through breach of a relation of trust and confidence," the complaint alleges. "HeLa cells are Mrs. Lacks's cells, taken by physicians in whom she had placed her trust without her consent or knowledge and for no therapeutic purpose."
By Charles Toutant | July 25, 2024
The suits stem from defendants' submission to the U.S. Food and Drug Administration of Abbreviated New Drug Applications [ANDA] seeking permission to manufacture generic versions of American Regent's selenious acid products before their patents expire.
By Charles Toutant | July 18, 2024
"We believed in our case, and that is why we committed so many resources to litigating it. And in the end, you know, I believe that we got a very excellent result," said Sherrie R. Savett of Berger Montague, who represented the plaintiff.
By Marianna Wharry | July 17, 2024
"The complaint generally alleges the elements for holding a medical provider strictly liable under a defective design theory, and AbbVie has not cited ... to a single case which addresses the pleading requirements in state court," wrote U.S. District Judge Robert Kirsch for the District of New Jersey. "In order for a court to find fraudulent joinder, 'it must be impossible for a state court to find that a plaintiff has stated a valid cause of action.'"
By Marianna Wharry | July 15, 2024
Saul Ewing's Sarah A. Sullivan and Alexander Lee Callo in Newark have recently entered appearances on behalf of an artificial intelligence-driven pharma-tech company sued in a pending securities class action.
By Colleen Murphy | June 18, 2024
"For over a decade, Amarin has engaged in a calculated anticompetitive scheme, whereby it executed exclusive, or de facto exclusive, agreements with suppliers to lock up the supply of Vascepa's active pharmaceutical ingredient, icosapent ethyl, in order to freeze its generic competitors out of the market and deprive consumers of affordable medication," the complaint said.
Presented by BigVoodoo
New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
McCarter & English, LLP, a well established and growing law firm, is actively seeking a talented and driven associate having 2-5 years o...
Gill & Chamas, LLC seeks a Personal Injury attorney to work in their Woodbridge, NJ office. Candidate must possess the following: ...
We are seeking an attorney with a minimum of four years of experience in transactional work to join our well-established, nationally renowne...